NanoViricides Prepares for Measles Drug Animal Study

NanoViricides, Inc., a company specializing in broad-spectrum antivirals, announced its upcoming animal study for Measles drug development. The study will evaluate drug candidates in specially modified mice to predict human treatment outcomes. President Anil R. Diwan expressed confidence in NV-387, a drug effective against RSV, potentially treating Measles due to their viral similarities.

The initiative addresses an urgent need as no approved Measles treatment exists. Despite Vitamin A and ribavirin being recommended, their efficacy and safety remain limited. Outbreaks continue to rise, with a noted decline in vaccination rates post-pandemic. NV-387's success could fill a crucial gap in combating this epidemic, especially with changing Measles virus genotypes challenging existing vaccines.